Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has shared an announcement.
Shin Nippon Biomedical Laboratories has released presentation materials for its consolidated financial results briefing for the third quarter of the fiscal year ending March 31, 2026. The briefing outlines the company’s Q3 performance and future outlook, presents details of its consolidated financial results, and highlights business topics across its nonclinical CRO, clinical CRO, and translational research/SGG segments, signaling continued emphasis on integrated drug development support services and providing stakeholders with structured insight into operational trends and strategic direction.
The most recent analyst rating on (JP:2395) stock is a Buy with a Yen1802.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) operates in the contract research organization (CRO) and translational research fields, providing nonclinical and clinical research services to pharmaceutical and biotech companies. The company focuses on supporting drug discovery and development through preclinical testing, clinical trial services, and related translational research solutions aimed at bridging laboratory findings to clinical applications.
Average Trading Volume: 285,930
Technical Sentiment Signal: Buy
Current Market Cap: Yen68.07B
See more data about 2395 stock on TipRanks’ Stock Analysis page.